The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MDS 2020 | Azacitidine in the treatment of MDS
David Steensma
• 5 Mar 2020
David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA, discusses azacitidine as the main treatment regimen for high-risk myelodysplastic syndrome (MDS) and the possibility of combination therapy. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
